285 related articles for article (PubMed ID: 21723456)
1. Cerebrospinal fluid oligoclonal bands in childhood opsoclonus-myoclonus.
Pranzatelli MR; Slev PR; Tate ED; Travelstead AL; Colliver JA; Joseph SA
Pediatr Neurol; 2011 Jul; 45(1):27-33. PubMed ID: 21723456
[TBL] [Abstract][Full Text] [Related]
2. Key role of CXCL13/CXCR5 axis for cerebrospinal fluid B cell recruitment in pediatric OMS.
Pranzatelli MR; Tate ED; McGee NR; Travelstead AL; Ransohoff RM; Ness JM; Colliver JA
J Neuroimmunol; 2012 Feb; 243(1-2):81-8. PubMed ID: 22264765
[TBL] [Abstract][Full Text] [Related]
3. Opsoclonus-myoclonus-dysequilibrium syndrome: cytological and immunological dynamics in the serial cerebrospinal fluid in two patients.
Bartos A; Pitha J
J Neurol; 2003 Dec; 250(12):1420-5. PubMed ID: 14673573
[TBL] [Abstract][Full Text] [Related]
4. Dexamethasone, Intravenous Immunoglobulin, and Rituximab Combination Immunotherapy for Pediatric Opsoclonus-Myoclonus Syndrome.
Pranzatelli MR; Tate ED
Pediatr Neurol; 2017 Aug; 73():48-56. PubMed ID: 28651977
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid in the pediatric opsoclonus-myoclonus syndrome.
Pranzatelli MR; Huang Y; Tate E; Stanley M; Noetzel MJ; Gospe SM; Banasiak K
Ann Neurol; 1995 Feb; 37(2):189-97. PubMed ID: 7531417
[TBL] [Abstract][Full Text] [Related]
6. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome.
Pranzatelli MR; Tate ED; Travelstead AL; Barbosa J; Bergamini RA; Civitello L; Franz DN; Greffe BS; Hanson RD; Hurwitz CA; Kalinyak KA; Kelfer H; Khakoo Y; Mantovani JF; Nicholson SH; Sanders JM; Wegner S
J Pediatr Hematol Oncol; 2006 Sep; 28(9):585-93. PubMed ID: 17006265
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Responsiveness to Reduced-Dose Rituximab in Corticotropin/Intravenous Immunoglobulin/Rituximab Combination Immunotherapy for Opsoclonus-Myoclonus Syndrome.
Pranzatelli MR; Tate ED; McGee NR; MacArthur CA
Pediatr Neurol; 2018 Aug; 85():71-75. PubMed ID: 30197220
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid ACTH and cortisol in opsoclonus-myoclonus: effect of therapy.
Pranzatelli MR; Chun KY; Moxness M; Tate ED; Allison TJ
Pediatr Neurol; 2005 Aug; 33(2):121-6. PubMed ID: 16087057
[TBL] [Abstract][Full Text] [Related]
9. Relation of intrathecal oligoclonal band production to inflammatory mediator and immunotherapy response in 208 children with OMS.
Pranzatelli MR; McGee NR; Tate ED
J Neuroimmunol; 2018 Aug; 321():150-156. PubMed ID: 29685330
[TBL] [Abstract][Full Text] [Related]
10. Oligoclonal bands in cerebrospinal fluid in patients with Tourette's syndrome.
Wenzel C; Wurster U; Müller-Vahl KR
Mov Disord; 2011 Feb; 26(2):343-6. PubMed ID: 20960488
[TBL] [Abstract][Full Text] [Related]
11. Trends and tenets in relapsing and progressive opsoclonus-myoclonus syndrome.
Pranzatelli MR; Tate ED
Brain Dev; 2016 May; 38(5):439-48. PubMed ID: 26786246
[TBL] [Abstract][Full Text] [Related]
12. Multiple sclerosis with uncommon cerebrospinal fluid findings.
Rot U; Mesec A; Pogacnik T
Croat Med J; 2003 Dec; 44(6):697-701. PubMed ID: 14652881
[TBL] [Abstract][Full Text] [Related]
13. Insights on chronic-relapsing opsoclonus-myoclonus from a pilot study of mycophenolate mofetil.
Pranzatelli MR; Tate ED; Travelstead AL; Baumgardner CA; Gowda NV; Halthore SN; Kerstan P; Kossak BD; Mitchell WG; Taub JW
J Child Neurol; 2009 Mar; 24(3):316-22. PubMed ID: 19258290
[TBL] [Abstract][Full Text] [Related]
14. Evidence of cellular immune activation in children with opsoclonus-myoclonus: cerebrospinal fluid neopterin.
Pranzatelli MR; Hyland K; Tate ED; Arnold LA; Allison TJ; Soori GS
J Child Neurol; 2004 Dec; 19(12):919-24. PubMed ID: 15704863
[TBL] [Abstract][Full Text] [Related]
15. Rituximab, IVIg, and Tetracosactide (ACTH1-24) Combination Immunotherapy ("RITE-CI") for Pediatric Opsoclonus-Myoclonus Syndrome: Immunomarkers and Clinical Observations.
Pranzatelli MR; Tate ED; Alber M; Awadalla M; Blumkin L; Lina ES; Leiz S; Móser J
Neuropediatrics; 2018 Apr; 49(2):123-134. PubMed ID: 29258131
[TBL] [Abstract][Full Text] [Related]
16. B cell depletion therapy for new-onset opsoclonus-myoclonus.
Pranzatelli MR; Tate ED; Swan JA; Travelstead AL; Colliver JA; Verhulst SJ; Crosley CJ; Graf WD; Joseph SA; Kelfer HM; Raju GP
Mov Disord; 2010 Jan; 25(2):238-42. PubMed ID: 20063398
[TBL] [Abstract][Full Text] [Related]
17. Long-term cerebrospinal fluid and blood lymphocyte dynamics after rituximab for pediatric opsoclonus-myoclonus.
Pranzatelli MR; Tate ED; Travelstead AL; Colliver JA
J Clin Immunol; 2010 Jan; 30(1):106-13. PubMed ID: 19838774
[TBL] [Abstract][Full Text] [Related]
18. [Opsoclonus myoclonus ataxia syndrome in Israel].
Blumkin L; Lerman-Sagie T
Harefuah; 2010 Jan; 149(1):24-8, 63. PubMed ID: 20422836
[TBL] [Abstract][Full Text] [Related]
19. CSF neurofilament light chain is elevated in OMS (decreasing with immunotherapy) and other pediatric neuroinflammatory disorders.
Pranzatelli MR; Tate ED; McGee NR; Verhulst SJ
J Neuroimmunol; 2014 Jan; 266(1-2):75-81. PubMed ID: 24342231
[TBL] [Abstract][Full Text] [Related]
20. Opsoclonus-myoclonus associated with celiac disease.
Deconinck N; Scaillon M; Segers V; Groswasser JJ; Dan B
Pediatr Neurol; 2006 Apr; 34(4):312-4. PubMed ID: 16638509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
